The Alzheimer's disease β-secretase enzyme, BACE1

Molecular Neurodegeneration

Volumn 2, Issue 1, 2007, Pages

  Cole, Sarah L ^a   Vassar, Robert ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MUS;

EID: 38349107593     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-2-22     Document Type: Article

References (244)

1. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. A Goate MC Chartier-Harlin M Mullan J Brown F Crawford L Fidani L Giuffra A Haynes N Irving L James R Mant P Newton K Rooke P Roques C Talbot M Pericak-Vance A Roses R Williamson M Rossor M Owen J Hardy, Nature 1991 349 704 706 10.1038/349704a0 1671712
2. Genetic linkage studies suggest that Alzheimer's disease is not a single homogeneous disorder. PH St. George-Hyslop JL Haines LA Farrer R Polinsky C Van Broeckhoven A Goate DR Crapper McLachlan H Orr AC Bruni S Sorbi I Rainero JF Foncin D Pollen JM Cantu R Tupler N Voskresenskaya R Mayeux J Growdon VA Fried RH Myers L Nee H Backhovens JJ Martin M Rossor MJ Owen M Mullan ME Percy H Karlinsky S Rich L Heston M Montesi M Mortilla N Nacmias JF Gusella JA Hardy, Nature 1990 347 194 197 10.1038/347194a0 2395471
3. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. GD Schellenberg TD Bird EM Wijsman HT Orr L Anderson E Nemens JA White L Bonnycastle JL Weber ME Alonso, Science 1992 258 5082 668 671 10.1126/science.1411576 1411576
4. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. E Levy-Lahad W Wasco P Poorkaj DM Romano J Oshima WH Pettingell CE Yu PD Jondro SD Schmidt K Wang, Science 1995 269 5226 973 977 10.1126/science.7638622 7638622
5. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. EH Corder AM Saunders WJ Strittmatter DE Schmechel PC Gaskell GW Small AD Roses JL Haines MA Pericak-Vance, Science 1993 261 921 923 10.1126/science.8346443 8346443
6. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. DL Sparks JC Hunsaker SW Scheff RJ Kryscio JL Henson WR Markesbery, Neurobiol Aging 1990 11 6 601 607 10.1016/0197-4580(90)90024-T 1704106
7. 15-year longitudinal study of blood pressure and dementia. I Skoog B Lernfelt S Landahl B Palmertz LA Andreasson L Nilsson G Persson A Oden A Svanborg, Lancet 1996 347 9009 1141 1145 10.1016/S0140-6736(96)90608-X 8609748
8. Severe cardiovascular disease and Alzheimer's disease: senile plaque formation in cortical areas. CF Soneira TM Scott, Clin Anat 1996 9 2 118 127 10.1002/(SICI)1098-2353(1996)9:2<118::AID-CA4>3.0.CO;2-D 8720786
9. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. M Kivipelto EL Helkala MP Laakso T Hanninen M Hallikainen K Alhainen S Iivonen A Mannermaa J Tuomilehto A Nissinen H Soininen, Ann Intern Med 2002 137 3 149 155 12160362
10. Hypertension and related factors in the etiology of Alzheimer's disease. I Skoog D Gustafson, Ann N Y Acad Sci 2002 977 29 36 12480731
11. Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. TE Golde D Dickson M Hutton, Curr Alzheimer Res 2006 3 5 421 430 10.2174/156720506779025189 17168641
12. Genetics of Alzheimer's disease. M Hutton J Perez-Tur J Hardy, Essays Biochem 1998 33 117 131 10488446
13. The role of Abeta 42 in Alzheimer's disease. SG Younkin, J Physiol (Paris) 1998 92 3-4 289 292 10.1016/S0928-4257(98)80035-1 9789825
14. Function and dysfunction of the presenilins. SS Sisodia SH Kim G Thinakaran, Am J Hum Genet 1999 65 1 7 12 10364510 10.1086/302475
15. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. A Rovelet-Lecrux D Hannequin G Raux N Le Meur A Laquerriere A Vital C Dumanchin S Feuillette A Brice M Vercelletto F Dubas T Frebourg D Campion, Nat Genet 2006 38 1 24 26 10.1038/ng1718 16369530
16. BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer's Disease. M Ohno EA Sametsky LH Younkin H Oakley SG Younkin M Citron R Vassar JF Disterhoft, Neuron 2004 41 1 27 33 10.1016/S0896-6273(03)00810-9 14715132
17. BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. M Ohno SL Cole M Yasvoina J Zhao M Citron R Berry JF Disterhoft R Vassar, Neurobiol Dis 2007 26 1 134 145 10.1016/j.nbd.2006.12.008 17258906
18. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. FM Laird H Cai AV Savonenko MH Farah K He T Melnikova H Wen HC Chiang G Xu VE Koliatsos DR Borchelt DL Price HK Lee PC Wong, J Neurosci 2005 25 50 11693 11709 10.1523/JNEUROSCI.2766-05.2005 16354928
19. Alzheimer's disease: genes, proteins, and therapy. DJ Selkoe, Physiol Rev 2001 81 2 741 766 11274343
20. BACE1: the beta-secretase enzyme in Alzheimer's disease. R Vassar, J Mol Neurosci 2004 23 1-2 105 114 10.1385/JMN:23:1-2:105 15126696
21. Identification of a novel aspartic protease (Asp 2) as b-Secretase. I Hussain D Powell DR Howlett DG Tew TD Meek C Chapman IS Gloger KE Murphy CD Southan DM Ryan TS Smith DL Simmons FS Walsh C Dingwall G Christie, Mol Cell Neurosci 1999 14 6 419 427 10.1006/mcne.1999.0811 10656250
22. Purification and cloning of amyloid precursor protein b-secretase from human brain. S Sinha JP Anderson R Barbour GS Basi R Caccavello D Davis M Doan HF Dovey N Frigon J Hong K Jacobson-Croak N Jewett P Keim J Knops I Lieberburg M Power H Tan G Tatsuno J Tung D Schenk P Seubert SM Suomensaari S Wang D Walker J Zhao L McConlogue V John, Nature 1999 402 6761 537 540 10.1038/990114 10591214
23. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. R Vassar BD Bennett S Babu-Khan S Kahn EA Mendiaz P Denis DB Teplow S Ross P Amarante R Loeloff Y Luo S Fisher J Fuller S Edenson J Lile MA Jarosinski AL Biere E Curran T Burgess JC Louis F Collins J Treanor G Rogers M Citron, Science 1999 286 5440 735 741 10.1126/science.286. 5440.735 10531052
24. Membrane-anchored aspartyl protease with Alzheimer's disease b-secretase activity. R Yan MJ Bienkowski ME Shuck H Miao MC Tory AM Pauley JR Brashler NC Stratman WR Mathews AE Buhl DB Carter AG Tomasselli LA Parodi RL Heinrikson ME Gurney, Nature 1999 402 6761 533 537 10.1038/990107 10591213
25. Human aspartic protease memapsin 2 cleaves the b-secretase site of b-amyloid precursor protein. X Lin G Koelsch S Wu D Downs A Dashti J Tang, Proc Natl Acad Sci USA 2000 97 4 1456 1460 10677483 10.1073/pnas.97.4.1456
26. Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease. MS Wolfe JDL Angeles DD Miller W Xia DJ Selkoe, Biochemistry 1999 38 35 11223 11230 10.1021/bi991080q 10471271
27. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. MS Wolfe W Xia BL Ostaszewski TS Diehl WT Kimberly DJ Selkoe, Nature 1999 398 6727 513 517 10.1038/19077 10206644
28. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and bAPP processing. G Yu M Nishimura S Arawaka D Levitan L Zhang A Tandon YQ Song E Rogaeva F Chen T Kawarai A Supala L Levesque H Yu DS Yang E Holmes P Milman Y Liang DM Zhang DH Xu C Sato E Rogaev M Smith C Janus Y Zhang R Aebersold LS Farrer S Sorbi A Bruni P Fraser P St George-Hyslop, Nature 2000 407 6800 48 54 10.1038/35024009 10993067
29. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. R Francis G McGrath J Zhang DA Ruddy M Sym J Apfeld M Nicoll M Maxwell B Hai MC Ellis AL Parks W Xu J Li M Gurney RL Myers CS Himes R Hiebsch C Ruble JS Nye D Curtis, Dev Cell 2002 3 1 85 97 10.1016/S1534-5807(02)00189-2 12110170
30. The role of presenilin cofactors in the gamma-secretase complex. N Takasugi T Tomita I Hayashi M Tsuruoka M Niimura Y Takahashi G Thinakaran T Iwatsubo, Nature 2003 422 6930 438 441 10.1038/nature01506 12660785
31. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. JD Buxbaum KN Liu Y Luo JL Slack KL Stocking JJ Peschon RS Johnson BJ Castner DP Cerretti RA Black, Journal of Biological Chemistry 1998 273 43 27765 27767 10.1074/jbc.273.43.27765 9774383
32. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. S Lammich E Kojro R Postina S Gilbert R Pfeiffer M Jasionowski C Haass F Fahrenholz, Proc Natl Acad Sci USA 1999 96 7 3922 3927 10097139 10.1073/pnas.96.7.3922
33. Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. X Cao TC Sudhof, J Biol Chem 2004 279 23 24601 24611 10.1074/jbc.M402248200 15044485
34. Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. DM Skovronsky DB Moore ME Milla RW Doms VM Lee, J Biol Chem 2000 275 4 2568 2575 10.1074/jbc.275.4.2568 10644715
35. Amyloid b-peptide is produced by cultured cells during normal metabolism. C Haass MG Schlossmacher AY Hung C Vigo-Pelfrey A Mellon BL Ostaszewski I Lieberburg EH Koo D Schenk DB Teplow DJ Selkoe, Nature 1992 359 322 325 10.1038/359322a0 1383826
36. Secretion of b-amyloid precursor protein cleaved at the amino-terminus of the b-amyloid peptide. P Seubert T Oltersdorf MG Lee R Barbour C Blomqist DL Davis K Bryant LC Fritz D Galasko LJ Thal I Lieberburg DB Schenk, Nature 1993 361 260 263 10.1038/361260a0 7678698
37. b-Secretase processing of the b-amyloid precursor protein in transgenic mice is efficient in neurons but inefficient in astrocytes. J Zhao L Paganini L Mucke M Gordon L Refolo M Carman S Sinha T Oltersdorf I Lieberburg L McConlogue, J Biol Chem 1996 271 49 31407 31411 10.1074/jbc.271.49.31407 8940150
38. Generation of amyloid b-protein from its precursor is sequence specific. M Citron DB Teplow DJ Selkoe, Neuron 1995 14 661 670 10.1016/0896-6273(95)90323- 2 7695913
39. b-amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. C Haass AY Hung MG Schlossmacher DB Teplow DJ Selkoe, J Biol Chem 1993 268 (5) 3021 3024 8428976
40. The vacuolar H+ ATPase inhibitor bafilomycin A1 differentially affects proteolytic processing of mutant and wild-type b-amyloid precursor protein. C Haass A Capell M Citron DB Teplow DJ Selkoe, J Biol Chem 1995 270 6186 6192 10.1074/jbc.270.11.6186 7890753
41. Cell-type and amyloid precursor protein-type specific inhibition of Ab release by bafilomycin A1, a selective inhibitor of vacuolar ATPases. J Knops S Suomensaari M Lee L McConlogue P Seubert S Sinha, J Biol Chem 1995 270 2419 2422 10.1074/jbc.270.6.2419 7852298
42. Evidence that production and release of amyloid b-protein involves the endocytic pathway. EH Koo S Squazzo, J Biol Chem 1994 269 17386 17389 8021238
43. The Swedish mutation causes early-onset Alzheimer's disease by b-secretase cleavage within the secretory pathway. C Haass CA Lemere A Capell M Citron P Seubert D Schenk L Lannfelt DJ Selkoe, Nature Med 1995 1 1291 1296 10.1038/nm1295-1291 7489411
44. Structural alterations in the peptide backbone of b-amyloid core protein may account for its deposition and stability in Alzheimer's disease. AE Roher JD Lowenson S Clarke C Wolkow R Wang RJ Cotter IM Reardon HA Zurcher-Neely RL Heinrikson MJ Ball BD Greenberg, J Biol Chem 1993 268 3072 3083 8428986
45. Inhibition of amyloid -protein production in neural cells by the serine protease inhibitor AEBSF. M Citron TS Diehl A Capell C Haass DB Teplow DJ Selkoe, Neuron 1996 17 171 179 10.1016/S0896-6273(00)80290-1 8755488
46. Generation and regulation of b-amyloid peptide variants by neurons. GK Gouras H Xu JN Jovanovic JD Buxbaum R Wang P Greengard NR Relkin G S., J Neurochem 1998 71 5 1920 1925 9798916
47. A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's b-secretase. BD Bennett P Denis M Haniu DB Teplow S Kahn JC Louis M Citron R Vassar, J Biol Chem 2000 275 48 37712 37717 10.1074/jbc.M005339200 10956649
48. Post-translational processing of beta-secretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production. S Benjannet A Elagoz L Wickham M Mamarbachi JS Munzer A Basak C Lazure JA Cromlish S Sisodia F Checler M Chretien NG Seidah, J Biol Chem 2001 276 14 10879 10887 10.1074/jbc.M009899200 11152688
49. Characterization of Alzheimer's b-secretase protein BACE. M Haniu P Denis Y Young EA Mendiaz J Fuller JO Hui BD Bennett S Kahn S Ross T Burgess V Katta G Rogers R Vassar M Citron, J Biol Chem 2000 275 28 21099 21106 10.1074/jbc.M002095200 10887202
50. Coordinated expression of b-amyloid precursor protein and the putative b-secretase BACE and a-secretase ADAM10 in mouse and human brain. M Marcinkiewicz NG Seidah, J Neurochem 2000 75 5 2133 2143 10.1046/j.1471-4159. 2000.0752133.x 11032903
51. A splice variant of b-secretase deficient in the amyloidogenic processing of the amyloid precursor protein. U Bodendorf F Fischer D Bodian G Multhaup P Paganetti, J Biol Chem 2001 276 15 12019 12023 10.1074/jbc.M008861200 11152683
52. Splice variants of the beta-site APP-cleaving enzyme BACE1 in human brain and pancreas. R Ehehalt B Michel D De Pietri Tonelli D Zacchetti K Simons P Keller, Biochem Biophys Res Commun 2002 293 1 30 37 10.1016/S0006-291X(02)00169- 9 12054559
53. BACE1 is the major b-secretase for generation of Ab peptides by neurons. H Cai Y Wang D McCarthy H Wen DR Borchelt DL Price PC Wong, Nature Neurosci 2001 4 3 233 234 10.1038/85064 11224536
54. Mice deficient in BACE1, the Alzheimers b-secretase, have normal phenotype and abolished b-amyloid generation. Y Luo B Bolon S Kahn BD Bennett S Babu-Khan P Denis W Fan H Kha J Zhang Y Gong L Martin JC Louis Q Yan WG Richards M Citron R Vassar, Nature Neurosci 2001 4 3 231 232 10.1038/85059 11224535
55. BACE knockout mice are healthy despite lacking the primary b-secretase activity in brain: implications for Alzheimer's disease therapeutics. SL Roberds J Anderson G Basi MJ Bienkowski DG Branstetter KS Chen SB Freedman NL Frigon D Games K Hu K Johnson-Wood KE Kappenman TT Kawabe I Kola R Kuehn M Lee W Liu R Motter NF Nichols M Power DW Robertson D Schenk M Schoor GM Shopp ME Shuck S Sinha KA Svensson G Tatsuno H Tintrup J Wijsman S Wright L McConlogue, Hum Mol Genet 2001 10 12 1317 1324 10.1093/hmg/10.12.1317 11406613
56. Correlative memory deficits, Ab elevation, and amyloid plaques in transgenic mice. K Hsiao P Chapman S Nilsen C Eckman Y Harigaya S Younkin F Yang G Cole, Science 1996 274 5284 99 103 10.1126/science.274.5284.99 8810256
57. BACE1 (b-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Y Luo B Bolon MA Damore D Fitzpatrick H Liu J Zhang Q Yan R Vassar M Citron, Neurobiol Dis 2003 4 1 81 88 10.1016/S0969-9961(03)00104-9
58. Water-soluble Ab (N-40, N-42) oligomers in normal and Alzheimer disease brains. YM Kuo MR Emmerling C Vigo-Pelfrey TC Kasunic JB Kirkpatrick GH Murdoch MJ Ball AE Roher, J Biol Chem 1996 271 8 4077 4081 10.1074/jbc.271.8.4077 8626743
59. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Y Gong L Chang KL Viola PN Lacor MP Lambert CE Finch GA Krafft WL Klein, Proc Natl Acad Sci U S A 2003 100 18 10417 10422 12925731 10.1073/pnas.1834302100
60. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. H Oakley SL Cole S Logan E Maus P Shao J Craft A Guillozet-Bongaarts M Ohno J Disterhoft L Van Eldik R Berry R Vassar, J Neurosci 2006 26 40 10129 10140 10.1523/JNEUROSCI.1202-06.2006 17021169
61. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. M Ohno L Chang W Tseng H Oakley M Citron WL Klein R Vassar JF Disterhoft, Eur J Neurosci 2006 23 1 251 260 10.1111/j.1460-9568.2005.04551.x 16420434
62. Genetic and pharmacological basis for therapeutic inhibition of beta- and gamma-secretases in mouse models of Alzheimer's memory deficits. M Ohno, Rev Neurosci 2006 17 4 429 454 17139843
63. BACE1 gene deletion: Impact on behavioral function in a model of Alzheimer's disease. D Kobayashi M Zeller T Cole M Buttini L McConlogue S Sinha S Freedman RG Morris KS Chen, Neurobiol Aging 2007 17331621
64. APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. H Yu CA Saura SY Choi LD Sun X Yang M Handler T Kawarabayashi L Younkin B Fedeles MA Wilson S Younkin ER Kandel A Kirkwood J Shen, Neuron 2001 31 5 713 726 10.1016/S0896-6273(01)00417-2 11567612
65. APP processing and synaptic function. F Kamenetz T Tomita H Hsieh G Seabrook D Borchelt T Iwatsubo S Sisodia R Malinow, Neuron 2003 37 6 925 937 10.1016/S0896-6273(03)00124-7 12670422
66. Amyloid beta peptide as a physiological modulator of neuronal 'A'-type K+ current. LD Plant NJ Webster JP Boyle M Ramsden DB Freir C Peers HA Pearson, Neurobiol Aging 2006 27 11 1673 1683 10.1016/j.neurobiolaging.2005.09.038 16271805
67. Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. H Ma S Lesne L Kotilinek JV Steidl-Nichols M Sherman L Younkin S Younkin C Forster N Sergeant A Delacourte R Vassar M Citron P Kofuji LM Boland KH Ashe, Proc Natl Acad Sci U S A 2007 104 19 8167 8172 17470798 10.1073/pnas.0609521104
68. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. O Singer RA Marr E Rockenstein L Crews NG Coufal FH Gage IM Verma E Masliah, Nat Neurosci 2005 8 10 1343 1349 10.1038/nn1531 16136043
69. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP transgenic mice. L McConlogue M Buttini JP Anderson EF Brigham KS Chen SB Freedman D Games K Johnson-Wood M Lee M Zeller W Liu R Motter S Sinha, J Biol Chem 2007 17616527
70. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. D Dominguez J Tournoy D Hartmann T Huth K Cryns S Deforce L Serneels IE Camacho E Marjaux K Craessaerts AJ Roebroek M Schwake R D'Hooge P Bach U Kalinke D Moechars C Alzheimer K Reiss P Saftig B De Strooper, J Biol Chem 2005 280 35 30797 30806 10.1074/jbc.M505249200 15987683
71. BACE1 (b-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. SM Harrison Harper, A.J., Hawkins, J., Duddy, G., Grau, E., Pugh, P.L., Winter, P.H., Shilliam, C.S., Hughes, Z.A., Dawson, L.A., Gonzalez, M.I., Upton, N., Pangalos, M.N., Molecular and Cellular Neuroscience 2003 24 646 655 10.1016/S1044-7431(03)00227-6
72. BACE maps to chromosome 11 and a BACE homolog, BACE2, reside in the obligate Down syndrome region of chromosome 21. AJ Saunders TW Kim RE Tanzi W Fan BD Bennett S Babu-Khan Y Luo JC Louis M McCaleb M Citron R Vassar WG Richards, Science 1999 286 5443 1255a 10.1126/science.286.5443.1255a
73. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. X Sun Y Wang H Qing MA Christensen Y Liu W Zhou Y Tong C Xiao Y Huang S Zhang X Liu W Song, Faseb J 2005 19 7 739 749 10.1096/fj.04-3426com 15857888
74. Expression analysis of BACE2 in brain and peripheral tissues. BD Bennett S Babu-Khan R Loeloff JC Louis E Curran M Citron R Vassar, J Biol Chem 2000 275 27 20647 20651 10.1074/jbc.M002688200 10749877
75. Prodomain processing of Asp1 (BACE2) is autocatalytic. I Hussain G Christie K Schneider S Moore C Dingwall, J Biol Chem 2001 276 26 23322 23328 10.1074/jbc.M101069200 11316808
76. BACE2, a b-secretase homolog, cleaves at the b site and within the amyloid-b region of the amyloid-b precursor protein. M Farzan CE Schnitzler N Vasilieva D Leung H Choe, Proc Natl Acad Sci USA 2000 97 17 9712 9717 10931940 10.1073/pnas.160115697
77. ASP1 (BACE2) cleaves the amyloid precursor protein at the b-secretase site. I Hussain DJ Powell DR Howlett GA Chapman L Gilmour PR Murdock DG Tew TD Meek C Chapman K Schneider SJ Ratcliffe D Tattersall TT Testa C Southan DM Ryan DL Simmons FS Walsh C Dingwall G Christie, Mol Cell Neurosci 2000 16 5 609 619 10.1006/mcne.2000.0884 11083922
78. BACE2 functions as an alternative a-secretase in cells. R Yan JB Munzner ME Shuck MJ Bienkowski, J Biol Chem 2001 276 36 34019 34027 10.1074/jbc. M105583200 11423558
79. Antagonistic effects of beta-site amyloid precursor protein-cleaving enzymes 1 and 2 on beta-amyloid peptide production in cells. G Basi N Frigon R Barbour T Doan G Gordon L McConlogue S Sinha M Zeller, J Biol Chem 2003 278 34 31512 31520 10.1074/jbc.M300169200 12801932
80. BACE2, as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome. X Sun G He W Song, Faseb J 2006 20 9 1369 1376 10.1096/fj.05-5632com 16816112
81. Transcriptional and translational regulation of BACE1 expression - implications for Alzheimer's disease. S Rossner M Sastre K Bourne SF Lichtenthaler, Prog Neurobiol 2006 79 2 95 111 10.1016/j.pneurobio.2006.06.001 16904810
82. Cloning and expression of the rat BACE1 promoter. C Lange-Dohna U Zeitschel F Gaunitz JR Perez-Polo V Bigl S Rossner, J Neurosci Res 2003 73 1 73 80 10.1002/jnr.10639 12815710
83. Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. MA Christensen W Zhou H Qing A Lehman S Philipsen W Song, Mol Cell Biol 2004 24 2 865 874 14701757 10.1128/MCB.24.2.865-874.2004
84. Functional characterization of the 5' flanking region of the BACE gene: identification of a 91 bp fragment involved in basal level of BACE promoter expression. YW Ge B Maloney K Sambamurti DK Lahiri, Faseb J 2004 18 9 1037 1039 15059977
85. Gene structure and organization of the human beta-secretase (BACE) promoter. K Sambamurti R Kinsey B Maloney YW Ge DK Lahiri, Faseb J 2004 18 9 1034 1036 15059975
86. Taking down the unindicted co-conspirators of amyloid beta-peptide-mediated neuronal death: shared gene regulation of BACE1 and APP genes interacting with CREB, Fe65 and YY1 transcription factors. DK Lahiri YW Ge JT Rogers K Sambamurti NH Greig B Maloney, Curr Alzheimer Res 2006 3 5 475 483 10.2174/156720506779025224 17168646
87. Inflammation and Alzheimer's disease. H Akiyama S Barger S Barnum B Bradt J Bauer GM Cole NR Cooper P Eikelenboom M Emmerling BL Fiebich CE Finch S Frautschy WS Griffin H Hampel M Hull G Landreth L Lue R Mrak IR Mackenzie PL McGeer MK O'Banion J Pachter G Pasinetti C Plata-Salaman J Rogers R Rydel Y Shen W Streit R Strohmeyer I Tooyoma FL Van Muiswinkel R Veerhuis D Walker S Webster B Wegrzyniak G Wenk T Wyss-Coray, Neurobiol Aging 2000 21 3 383 421 10.1016/S0197-4580(00)00124-X 10858586
88. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. M Sastre I Dewachter S Rossner N Bogdanovic E Rosen P Borghgraef BO Evert L Dumitrescu-Ozimek DR Thal G Landreth J Walter T Klockgether F van Leuven MT Heneka, Proc Natl Acad Sci U S A 2006 103 2 443 448 16407166 10.1073/pnas.0503839103
89. Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. KZ Bourne DC Ferrari C Lange-Dohna S Rossner TG Wood JR Perez-Polo, J Neurosci Res 2007 85 6 1194 1204 10.1002/jnr.21252 17385716
90. Costimulatory effects of interferon-g and interleukin-1b or tumor necrosis factor a on the synthesis of Ab1-40 and Ab1-42 by human astrocytes. I Blasko R Veerhuis M Stampfer-Kountchev M Saurwein-Teissl P Eikelenboom B Grubeck-Loebenstein, Neurobiol Dis 2000 7 682 689 10.1006/nbdi.2000.0321 11114266
91. Interferon gamma stimulates beta-secretase expression and sAPPbeta production in astrocytes. HS Hong EM Hwang HJ Sim HJ Cho JH Boo SS Oh SU Kim I Mook-Jung, Biochem Biophys Res Commun 2003 307 4 922 927 10.1016/S0006-291X(03) 01270-1 12878199
92. IFN-gamma-induced BACE1 expression is mediated by activation of JAK2 and ERK1/2 signaling pathways and direct binding of STAT1 to BACE1 promoter in astrocytes. HJ Cho SK Kim SM Jin EM Hwang YS Kim K Huh I Mook-Jung, Glia 2007 55 3 253 262 10.1002/glia.20451 17091494
93. Neuronal and glial b-secretase (BACE) protein expression in transgenic Tg2576 mice with amyloid plaque pathology. S Rossner J Apelt R Schliebs JR Perez-Polo V Bigl, J Neurosci Res 2001 64 5 437 446 10.1002/jnr.1095 11391698
94. Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent. M Hartlage-Rubsamen U Zeitschel J Apelt U Gartner H Franke T Stahl A Gunther R Schliebs M Penkowa V Bigl S Rossner, Glia 2003 41 2 169 179 10.1002/glia.10178 12509807
95. Neuronal and nonneuronal quantitative BACE immunocytochemical expression in the entorhinohippocampal and frontal regions in Alzheimer's disease. G Leuba G Wernli A Vernay R Kraftsik MH Mohajeri KD Saini, Dement Geriatr Cogn Disord 2005 19 4 171 183 10.1159/000083496 15677864
96. Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme. S Rossner C Lange-Dohna U Zeitschel JR Perez-Polo, J Neurochem 2005 92 2 226 234 10.1111/j.1471-4159.2004.02857.x 15663471
97. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J Zhao Y Fu M Yasvoina P Shao B Hitt T O'Connor S Logan E Maus M Citron R Berry L Binder R Vassar, J Neurosci 2007 27 14 3639 3649 10.1523/JNEUROSCI.4396-06.2007 17409228
98. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. MT Heneka M Sastre L Dumitrescu-Ozimek A Hanke I Dewachter C Kuiperi K O'Banion T Klockgether F Van Leuven GE Landreth, Brain 2005 128 Pt 6 1442 1453 10.1093/brain/awh452 15817521
99. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice. MT Heneka M Sastre L Dumitrescu-Ozimek I Dewachter J Walter T Klockgether F Van Leuven, J Neuroinflammation 2005 2 22 16212664 10.1186/1742-2094-2-22
100. Expression of beta-secretase mRNA in transgenic Tg2576 mouse brain with Alzheimer plaque pathology. M Bigl J Apelt EA Luschekina C Lange-Dohna S Rossner R Schliebs, Neurosci Lett 2000 292 2 107 110 10.1016/S0304-3940(00)01452-X 10998560
101. beta-site APP cleaving enzyme mRNA expression in APP transgenic mice: anatomical overlap with transgene expression and static levels with aging. MC Irizarry JJ Locascio BT Hyman, Am J Pathol 2001 158 1 173 177 11141490
102. Expression of the Alzheimer protease BACE1 is suppressed via its 5'-untranslated region. S Lammich S Schobel AK Zimmer SF Lichtenthaler C Haass, EMBO Rep 2004 5 6 620 625 15167888 10.1038/sj.embor.7400166
103. Differential utilization of upstream AUGs in the beta-secretase mRNA suggests that a shunting mechanism regulates translation. GW Rogers Jr. GM Edelman VP Mauro, Proc Natl Acad Sci U S A 2004 101 9 2794 2799 14981268 10.1073/pnas.0308576101
104. Translational regulation of BACE-1 expression in neuronal and non-neuronal cells. D De Pietri Tonelli M Mihailovich A Di Cesare F Codazzi F Grohovaz D Zacchetti, Nucleic Acids Res 2004 32 5 1808 1817 15034149 10.1093/nar/gkh348
105. Maturation and pro-peptide cleavage of beta-secretase. A Capell H Steiner M Willem H Kaiser C Meyer J Walter S Lammich G Multhaup C Haass, J Biol Chem 2000 275 40 30849 30854 10.1074/jbc.M003202200 10801872
106. Maturation and endosomal targeting of b-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease b-secretase. JT Huse DS Pijak GJ Leslie VM Lee RW Doms, J Biol Chem 2000 275 43 33729 33737 10.1074/jbc.M004175200 10924510
107. Processing of b-secretase by furin and other members of the proprotein convertase family. JW Creemers D Ines Dominguez E Plets L Serneels NA Taylor G Multhaup K Craessaerts W Annaert B De Strooper, J Biol Chem 2001 276 6 4211 4217 10.1074/jbc.M006947200 11071887
108. Characterization of the glycosylation profiles of Alzheimer's b-secretase protein Asp-2 expressed in a variety of cell lines. J Charlwood C Dingwall R Matico I Hussain K Johanson S Moore DJ Powell JM Skehel S Ratcliffe B Clarke J Trill S Sweitzer P Camilleri, J Biol Chem 2001 276 20 16739 16748 10.1074/jbc.M009361200 11278492
109. Characterization of the ectodomain shedding of the beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1). I Hussain J Hawkins A Shikotra DR Riddell A Faller C Dingwall, J Biol Chem 2003 278 38 36264 36268 10.1074/jbc.M304186200 12857759
110. Extracellular release of BACE1 holoproteins from human neuronal cells. KS Murayama F Kametani W Araki, Biochem Biophys Res Commun 2005 338 2 800 807 10.1016/j.bbrc.2005.10.015 16243299
111. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. JH Verheijen LG Huisman N van Lent U Neumann P Paganetti CE Hack F Bouwman J Lindeman EL Bollen R Hanemaaijer, Clin Chem 2006 52 6 1168 1174 10.1373/clinchem.2006.066720 16614000
112. Compartmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. DR Riddell G Christie I Hussain C Dingwall, Curr Biol 2001 11 16 1288 1293 10.1016/S0960-9822(01)00394-3 11525745
113. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. R Ehehalt P Keller C Haass C Thiele K Simons, J Cell Biol 2003 160 1 113 123 10.1083/jcb.200207113 12515826
114. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. J Cordy M, I Hussain C Dingwall NM Hooper AJ Turner, Proc Natl Acad Sci U S A 2003 100 20 11735 11740 14504402 10.1073/pnas.1635130100
115. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. L Kalvodova N Kahya P Schwille R Ehehalt P Verkade D Drechsel K Simons, J Biol Chem 2005 280 44 36815 36823 10.1074/jbc.M504484200 16115865
116. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. L Puglielli BC Ellis AJ Saunders DM Kovacs, J Biol Chem 2003 278 22 19777 19783 10.1074/jbc.M300466200 12649271
117. Human BACE forms dimers and colocalizes with APP. A Schmechel M Strauss A Schlicksupp R Pipkorn C Haass TA Bayer G Multhaup, J Biol Chem 2004 279 38 39710 39717 10.1074/jbc.M402785200 15247262
118. Dimerization of beta-site beta-amyloid precursor protein-cleaving enzyme. GG Westmeyer M Willem SF Lichtenthaler G Lurman G Multhaup I Assfalg-Machleidt K Reiss P Saftig C Haass, J Biol Chem 2004 279 51 53205 53212 10.1074/jbc.M410378200 15485862
119. PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein. J Xie Q Guo, J Biol Chem 2005 280 14 13824 13832 10.1074/jbc.M411933200 15671026
120. BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. B Angeletti KJ Waldron KB Freeman H Bawagan I Hussain CC Miller KF Lau ME Tennant C Dennison NJ Robinson C Dingwall, J Biol Chem 2005 280 18 17930 17937 10.1074/jbc.M412034200 15722349
121. Beta-amyloid protein converting enzyme 1 and brain-specific type II membrane protein BRI3: binding partners processed by furin. L Wickham S Benjannet E Marcinkiewicz M Chretien NG Seidah, J Neurochem 2005 92 1 93 102 10.1111/j.1471-4159.2004.02840.x 15606899
122. Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-secretase. Z Scholefield EA Yates G Wayne A Amour W McDowell JE Turnbull, J Cell Biol 2003 163 1 97 107 10.1083/jcb.200303059 14530380
123. Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation. W He Y Lu I Qahwash XY Hu A Chang R Yan, Nat Med 2004 10 9 959 965 10.1038/nm1088 15286784
124. Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. R Spoelgen CA von Arnim AV Thomas ID Peltan M Koker A Deng MC Irizarry OM Andersen TE Willnow BT Hyman, J Neurosci 2006 26 2 418 428 10.1523/JNEUROSCI.3882-05. 2006 16407538
125. Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer's disease. JT Huse RW Doms, Mol Neurobiol 2000 22 1-3 81 98 10.1385/MN:22:1-3:081 11414282
126. Phosphorylation regulates intracellular trafficking of beta-secretase. J Walter R Fluhrer B Hartung M Willem C Kaether A Capell S Lammich G Multhaup C Haass, J Biol Chem 2001 276 18 14634 14641 10.1074/jbc.M011116200 11278841
127. The carboxyl-terminus of BACE contains a sorting signal that regulates BACE trafficking but not the formation of total A(beta). L Pastorino AF Ikin AC Nairn A Pursnani JD Buxbaum, Mol Cell Neurosci 2002 19 2 175 185 10.1006/mcne.2001.1065 11860271
128. Memapsin 2 (beta-secretase) cytosolic domain binds to the VHS domains of GGA1 and GGA2: implications on the endocytosis mechanism of memapsin 2. X He WP Chang G Koelsch J Tang, FEBS Lett 2002 524 1-3 183 187 12135764
129. Insights into the phosphoregulation of beta-secretase sorting signal by the VHS domain of GGA1. T Shiba S Kametaka M Kawasaki M Shibata S Waguri Y Uchiyama S Wakatsuki, Traffic 2004 5 6 437 448 10.1111/j.1600-0854.2004.00188.x 15117318
130. Demonstration of BACE (beta-secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopy. CA von Arnim MM Tangredi ID Peltan BM Lee MC Irizarry A Kinoshita BT Hyman, J Cell Sci 2004 117 Pt 22 5437 5445 10.1242/jcs.01422 15466887
131. GGA proteins mediate the recycling pathway of memapsin 2 (BACE). X He F Li WP Chang J Tang, J Biol Chem 2005 280 12 11696 11703 10.1074/jbc.M411296200 15615712
132. GGA proteins regulate retrograde transport of BACE1 from endosomes to the trans-Golgi network. T Wahle K Prager N Raffler C Haass M Famulok J Walter, Mol Cell Neurosci 2005 29 3 453 461 10.1016/j.mcn.2005.03.014 15886016
133. Interactions of GGA3 with the ubiquitin sorting machinery. R Puertollano JS Bonifacino, Nat Cell Biol 2004 6 3 244 251 10.1038/ncb1106 15039775
134. BACE is degraded via the lysosomal pathway. YH Koh CA von Arnim BT Hyman RE Tanzi G Tesco, J Biol Chem 2005 280 37 32499 32504 10.1074/jbc.M506199200 16033761
135. GGA1 acts as a spatial switch altering amyloid precursor protein trafficking and processing. CA von Arnim R Spoelgen ID Peltan M Deng S Courchesne M Koker T Matsui H Kowa SF Lichtenthaler MC Irizarry BT Hyman, J Neurosci 2006 26 39 9913 9922 10.1523/JNEUROSCI.2290-06.2006 17005855
136. Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. G Tesco YH Koh EL Kang AN Cameron S Das M Sena-Esteves M Hiltunen SH Yang Z Zhong Y Shen JW Simpkins RE Tanzi, Neuron 2007 54 5 721 737 10.1016/j.neuron.2007.05. 012 17553422
137. Apical sorting of beta-secretase limits amyloid beta-peptide production. A Capell L Meyn R Fluhrer DB Teplow J Walter C Haass, J Biol Chem 2002 277 7 5637 5643 10.1074/jbc.M109119200 11741885
138. The beta-amyloid-related proteins presenilin 1 and BACE1 are axonally transported to nerve terminals in the brain. JG Sheng DL Price VE Koliatsos, Exp Neurol 2003 184 2 1053 1057 10.1016/j.expneurol.2003.08.018 14769400
139. Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. O Lazarov M Lee DA Peterson SS Sisodia, J Neurosci 2002 22 22 9785 9793 12427834
140. Endoproteolysis of beta-secretase (beta-site amyloid precursor protein-cleaving enzyme) within its catalytic domain. A potential mechanism for regulation. JT Huse D Byant Y Yang DS Pijak I D'Souza JJ Lah VM Lee RW Doms DG Cook, J Biol Chem 2003 278 19 17141 17149 10.1074/jbc.M213303200 12551920
141. Degradation of BACE by the ubiquitin-proteasome pathway. H Qing W Zhou MA Christensen X Sun Y Tong W Song, Faseb J 2004 18 13 1571 1573 15289451
142. Modeling of substrate specificity of the Alzheimer's disease amyloid precursor protein b-secretase. JM Sauder JW Arthur RL Dunbrack Jr., J Mol Biol 2000 300 2 241 248 10.1006/jmbi.2000.3860 10873463
143. Structure of the protease domain of memapsin 2 (b-secretase) complexed with inhibitor. L Hong G Koelsch X Lin S Wu S Terzyan AK Ghosh XC Zhang J Tang, Science 2000 290 5489 150 153 10.1126/science.290.5489.150 11021803
144. Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. Q Li TC Sudhof, J Biol Chem 2004 279 11 10542 10550 10.1074/jbc.M310001200 14699153
145. BACE (beta-secretase) modulates the processing of APLP2 in vivo. L Pastorino AF Ikin S Lamprianou N Vacaresse JP Revelli K Platt P Paganetti PM Mathews S Harroch JD Buxbaum, Mol Cell Neurosci 2004 25 4 642 649 10.1016/j.mcn.2003.12.013 15080893
146. Processing of beta-amyloid precursor-like protein-1 and -2 by gamma-secretase regulates transcription. MH Scheinfeld E Ghersi K Laky BJ Fowlkes L D'Adamio, J Biol Chem 2002 277 46 44195 44201 10.1074/jbc.M208110200 12228233
147. Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. R Pardossi-Piquard A Petit T Kawarai C Sunyach C Alves da Costa B Vincent S Ring L D'Adamio J Shen U Muller P St George Hyslop F Checler, Neuron 2005 46 4 541 554 10.1016/j.neuron.2005.04.008 15944124
148. Bace1 modulates myelination in the central and peripheral nervous system. X Hu CW Hicks W He P Wong WB Macklin BD Trapp R Yan, Nat Neurosci 2006 9 12 1520 1525 10.1038/nn1797 17099708
149. Control of peripheral nerve myelination by the beta-secretase BACE1. M Willem AN Garratt B Novak M Citron S Kaufmann A Rittger B DeStrooper P Saftig C Birchmeier C Haass, Science 2006 314 5799 664 666 10.1126/science.1132341 16990514
150. Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. A Kamal A Almenar-Queralt JF LeBlanc EA Roberts LS Goldstein, Nature 2001 414 6864 643 648 10.1038/414643a 11740561
151. beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. HK Wong T Sakurai F Oyama K Kaneko K Wada H Miyazaki M Kurosawa B De Strooper P Saftig N Nukina, J Biol Chem 2005 280 24 23009 23017 10.1074/jbc.M414648200 15824102
152. BACE1 regulates voltage-gated sodium channels and neuronal activity. DY Kim BW Carey H Wang LA Ingano AM Binshtok MH Wertz WH Pettingell P He VM Lee CJ Woolf DM Kovacs, Nat Cell Biol 2007 9 7 755 764 10.1038/ncb1602 17576410
153. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. JR Cirrito KA Yamada MB Finn RS Sloviter KR Bales PC May DD Schoepp SM Paul S Mennerick DM Holtzman, Neuron 2005 48 6 913 922 10.1016/j.neuron.2005.10. 028 16364896
154. Remarkable roles of proteolysis on and beyond the cell surface. CP Blobel, Curr Opin Cell Biol 2000 12 5 606 612 10.1016/S0955-0674(00)00139-3 10978897
155. The endocytic receptor protein LRP also mediates neuronal calcium signaling via N-methyl-D-aspartate receptors. BJ Bacskai MQ Xia DK Strickland GW Rebeck BT Hyman, Proc Natl Acad Sci U S A 2000 97 21 11551 11556 11016955 10.1073/pnas.200238297
156. Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein. E Van Uden M Mallory I Veinbergs M Alford E Rockenstein E Masliah, J Neurosci 2002 22 21 9298 9304 12417655
157. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. CA von Arnim A Kinoshita ID Peltan MM Tangredi L Herl BM Lee R Spoelgen TT Hshieh S Ranganathan FD Battey CX Liu BJ Bacskai S Sever MC Irizarry DK Strickland BT Hyman, J Biol Chem 2005 280 18 17777 17785 10.1074/jbc.M414248200 15749709
158. Low density lipoprotein receptor-related protein (LRP) interacts with presenilin 1 and is a competitive substrate of the amyloid precursor protein (APP) for gamma-secretase. A Lleo E Waldron CA von Arnim L Herl MM Tangredi ID Peltan DK Strickland EH Koo BT Hyman CU Pietrzik O Berezovska, J Biol Chem 2005 280 29 27303 27309 10.1074/jbc.M413969200 15917251
159. Clinical aspects of inflammation in Alzheimer's disease. PB Rosenberg, Int Rev Psychiatry 2005 17 6 503 514 10.1080/02646830500382037 16401549
160. The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. SF Lichtenthaler DI Dominguez GG Westmeyer K Reiss C Haass P Saftig B De Strooper B Seed, J Biol Chem 2003 278 49 48713 48719 10.1074/jbc.M303861200 14507929
161. Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. S Kitazume Y Tachida R Oka K Shirotani TC Saido Y Hashimoto, Proc Natl Acad Sci U S A 2001 98 24 13554 13559 11698669 10.1073/pnas.241509198
162. In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase. S Kitazume K Nakagawa R Oka Y Tachida K Ogawa Y Luo M Citron H Shitara C Taya H Yonekawa JC Paulson E Miyoshi N Taniguchi Y Hashimoto, J Biol Chem 2005 280 9 8589 8595 10.1074/jbc.M409417200 15364953
163. Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients. A Garlind A Brauner B Hojeberg H Basun M Schultzberg, Brain Res 1999 826 1 112 116 10.1016/S0006-8993(99)01092-6 10216202
164. Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase. PH Kuhn E Marjaux A Imhof B De Strooper C Haass SF Lichtenthaler, J Biol Chem 2007 282 16 11982 11995 10.1074/jbc. M700356200 17307738
165. Beta-secretase activity increases with aging in human, monkey, and mouse brain. H Fukumoto DL Rosene MB Moss S Raju BT Hyman MC Irizarry, Am J Pathol 2004 164 2 719 725 14742275
166. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. H Fukumoto BS Cheung BT Hyman MC Irizarry, Arch Neurol 2002 59 9 1381 1389 10.1001/archneur.59.9.1381 12223024
167. alpha- and beta-secretase: profound changes in Alzheimer's disease. SJ Tyler D Dawbarn GK Wilcock SJ Allen, Biochem Biophys Res Commun 2002 299 3 373 376 10.1016/S0006-291X(02)02635-9 12445809
168. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. RM Holsinger CA McLean K Beyreuther CL Masters G Evin, Ann Neurol 2002 51 6 783 786 10.1002/ana.10208 12112088
169. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. LB Yang K Lindholm R Yan M Citron W Xia XL Yang T Beach L Sue P Wong D Price R Li Y Shen, Nat Med 2003 9 1 3 4 10.1038/nm0103-3 12514700
170. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. R Li K Lindholm LB Yang X Yue M Citron R Yan T Beach L Sue M Sabbagh H Cai P Wong D Price Y Shen, Proc Natl Acad Sci U S A 2004 101 10 3632 3637 14978286 10.1073/pnas.0205689101
171. Beta-site APP cleaving enzyme 1 (BACE1) is increased in remaining neurons in Alzheimer's disease brains. H Harada A Tamaoka K Ishii S Shoji S Kametaka F Kametani Y Saito S Murayama, Neurosci Res 2006 54 1 24 29 10.1016/j.neures.2005. 10.001 16290302
172. Gene dosage of the amyloid beta precursor protein in Alzheimer's disease. MB Podlisny G Lee DJ Selkoe, Science 1987 238 4827 669 671 10.1126/science. 2960019 2960019
173. Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome. X Sun Y Tong H Qing CH Chen W Song, Faseb J 2006 20 9 1361 1368 10.1096/fj.05-5628com 16816111
174. Proteomics-driven progress in neurodegeneration research. M Fountoulakis S Kossida, Electrophoresis 2006 27 8 1556 1573 10.1002/elps.200500738 16555340
175. Control of APP processing and Abeta generation level by BACE1 enzymatic activity and transcription. Y Li W Zhou Y Tong G He W Song, Faseb J 2006 20 2 285 292 10.1096/fj.05-4986com 16449801
176. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. DA Snowdon LH Greiner JA Mortimer KP Riley PA Greiner WR Markesbery, Jama 1997 277 10 813 817 10.1001/jama.277.10.813 9052711
177. Absence of vascular dementia in an autopsy series from a dementia clinic. KA Nolan MM Lino AW Seligmann JP Blass, J Am Geriatr Soc 1998 46 5 597 604 9588373
178. Accumulation of the beta amyloid precursor protein at sites of ischemic injury in rat brain. RN Kalaria SU Bhatti EA Palatinsky DH Pennington ER Shelton HW Chan G Perry WD Lust, Neuroreport 1993 4 2 211 214 10.1097/00001756- 199302000-00025 8453062
179. Effect of vascular lesions on cognition in Alzheimer's disease: a community-based study. RG Riekse JB Leverenz W McCormick JD Bowen L Teri D Nochlin K Simpson C Eugenio EB Larson D Tsuang, J Am Geriatr Soc 2004 52 9 1442 1448 15341544 10.1111/j.1532-5415.2004.52405.x
180. AD lesions and infarcts in demented and non-demented Japanese-American men. H Petrovitch GW Ross SC Steinhorn RD Abbott W Markesbery D Davis J Nelson J Hardman K Masaki MR Vogt L Launer LR White, Ann Neurol 2005 57 1 98 103 10.1002/ana.20318 15562458
181. How do heart disease and stroke become risk factors for Alzheimer's disease? JC de la Torre, Neurol Res 2006 28 6 637 644 10.1179/016164106X130362 16945216
182. Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. AE Roher C Esh TA Kokjohn W Kalback DC Luehrs JD Seward LI Sue TG Beach, Arterioscler Thromb Vasc Biol 2003 23 11 2055 2062 10.1161/01.ATV.0000095973.42032.44 14512367
183. Atherosclerosis and neurodegeneration: unexpected conspirators in Alzheimer's dementia. C Iadecola, Arterioscler Thromb Vasc Biol 2003 23 11 1951 1953 10.1161/01.ATV.0000102660.99744.85 14617615
184. Neurovascular regulation in the normal brain and in Alzheimer's disease. C Iadecola, Nat Rev Neurosci 2004 5 5 347 360 10.1038/nrn1387 15100718
185. Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. TG Beach JR Wilson LI Sue A Newell M Poston R Cisneros Y Pandya C Esh DJ Connor M Sabbagh DG Walker AE Roher, Acta Neuropathol (Berl) 2007 113 1 13 21 10.1007/s00401-006-0136-y
186. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. A Hofman A Ott MM Breteler ML Bots AJ Slooter F van Harskamp CN van Duijn C Van Broeckhoven DE Grobbee, Lancet 1997 349 9046 151 154 10.1016/S0140-6736(96)09328-2 9111537
187. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. MM Breteler, Neurobiol Aging 2000 21 2 153 160 10.1016/S0197- 4580(99)00110-4 10867200
188. Blood pressure and dementia in persons 75+ years old: 3-year follow-up results from the Kungsholmen Project. Z Guo C Qiu M Viitanen J Fastbom B Winblad L Fratiglioni, J Alzheimers Dis 2001 3 6 585 591 12214025
189. Demonstrating the case that AD is a vascular disease: epidemiologic evidence. LJ Launer, Ageing Res Rev 2002 1 1 61 77 10.1016/S0047-6374(01)00364-5 12039449
190. Perfusion abnormalities in prodromal AD. KA Johnson MS Albert, Neurobiol Aging 2000 21 2 289 292 10.1016/S0197-4580(00)00137-8 10867213
191. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. D Kogure H Matsuda T Ohnishi T Asada M Uno T Kunihiro S Nakano M Takasaki, J Nucl Med 2000 41 7 1155 1162 10914904
192. Hippocampal perfusion in mild Alzheimer's disease. G Rodriguez P Vitali P Calvini C Bordoni N Girtler G Taddei G Mariani F Nobili, Psychiatry Res 2000 100 2 65 74 10.1016/S0925-4927(00)00071-8 11114492
193. Is Alzheimer's disease preceded by neurodegeneration or cerebral hypoperfusion? JC de la Torre, Ann Neurol 2005 57 6 783 784 10.1002/ana.20516 15929049
194. Preclinical prediction of Alzheimer's disease using SPECT. KA Johnson K Jones BL Holman JA Becker PA Spiers A Satlin MS Albert, Neurology 1998 50 6 1563 1571 9633695
195. Critical threshold cerebral hypoperfusion causes Alzheimer's disease? JC de la Torre, Acta Neuropathol (Berl) 1999 98 1 1 8 10.1007/s004010051044
196. Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. JS Meyer G Rauch RA Rauch A Haque, Neurobiol Aging 2000 21 2 161 169 10.1016/S0197-4580(00)00136-6 10867201
197. Volume cerebral blood flow reduction in pre-clinical stage of Alzheimer disease: evidence from an ultrasonographic study. N Maalikjy Akkawi B Borroni C Agosti M Magoni M Broli A Pezzini A Padovani, J Neurol 2005 252 5 559 563 10.1007/s00415-005-0689-z 15726249
198. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. A Ruitenberg T den Heijer SL Bakker JC van Swieten PJ Koudstaal A Hofman MM Breteler, Ann Neurol 2005 57 6 789 794 10.1002/ana.20493 15929050
199. Cerebrovascular reactivity and cognitive decline in patients with Alzheimer disease. M Silvestrini P Pasqualetti R Baruffaldi M Bartolini Y Handouk M Matteis F Moffa L Provinciali F Vernieri, Stroke 2006 37 4 1010 1015 10.1161/01.STR.0000206439.62025.97 16497984
200. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. LM Sayre DA Zelasko PL Harris G Perry RG Salomon MA Smith, J Neurochem 1997 68 5 2092 2097 9109537
201. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. TI Williams BC Lynn WR Markesbery MA Lovell, Neurobiol Aging 2006 27 8 1094 1099 10.1016/j.neurobiolaging.2005.06.004 15993986
202. Positron emission tomographic studies of aging and Alzheimer disease. MJ de Leon SH Ferris AE George DR Christman JS Fowler C Gentes B Reisberg B Gee M Emmerich Y Yonekura J Brodie Kricheff AP Wolf, AJNR Am J Neuroradiol 1983 4 3 568 571 6410799
203. Functional brain imaging in the resting state and during activation in Alzheimer's disease. Implications for disease mechanisms involving oxidative phosphorylation. SI Rapoport, Ann N Y Acad Sci 1999 893 138 153 10.1111/j.1749-6632.1999.tb07823.x 10672235
204. In vivo PET imaging and postmortem studies suggest potentially reversible and irreversible stages of brain metabolic failure in Alzheimer's disease. SI Rapoport, Eur Arch Psychiatry Clin Neurosci 1999 249 Suppl 3 46 55 10654100
205. Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. HK Shin PB Jones M Garcia-Alloza L Borrelli SM Greenberg BJ Bacskai MP Frosch BT Hyman MA Moskowitz C Ayata, Brain 2007
206. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. DL Sparks SW Scheff JC Hunsaker H Liu T Landers DR Gross, Exp Neurol 1994 126 1 88 94 10.1006/exnr.1994.1044 8157129
207. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations. DL Sparks YM Kuo A Roher T Martin RJ Lukas, Ann N Y Acad Sci 2000 903 335 344 10.1111/j.1749-6632. 2000.tb06384.x 10818523
208. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. K Fassbender M Simons C Bergmann M Stroick D Lutjohann P Keller H Runz S Kuhl T Bertsch K von Bergmann M Hennerici K Beyreuther T Hartmann, Proc Natl Acad Sci USA 2001 98 10 5856 5861 11296263 10.1073/pnas.081620098
209. High cholesterol content in neurons increases BACE, beta-amyloid, and phosphorylated tau levels in rabbit hippocampus. O Ghribi B Larsen M Schrag MM Herman, Exp Neurol 2006 200 2 460 467 10.1016/j.expneurol.2006.03.019 16696972
210. Oxidative stress increases expression and activity of BACE in NT2 neurons. E Tamagno P Bardini A Obbili A Vitali R Borghi D Zaccheo MA Pronzato O Danni MA Smith G Perry M Tabaton, Neurobiol Dis 2002 10 3 279 288 10.1006/nbdi.2002.0515 12270690
211. Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. E Tamagno M Parola P Bardini A Piccini R Borghi M Guglielmotto G Santoro A Davit O Danni MA Smith G Perry M Tabaton, J Neurochem 2005 92 3 628 636 10.1111/j.1471-4159.2004.02895.x 15659232
212. Oxidative stress potentiates BACE1 gene expression and Abeta generation. Y Tong W Zhou V Fung MA Christensen H Qing X Sun W Song, J Neural Transm 2005 112 3 455 469 10.1007/s00702-004-0255-3 15614428
213. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. RA Velliquette T O'Connor R Vassar, J Neurosci 2005 25 47 10874 10883 10.1523/JNEUROSCI.2350-05.2005 16306400
214. Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression. X Sun G He H Qing W Zhou F Dobie F Cai M Staufenbiel LE Huang W Song, Proc Natl Acad Sci U S A 2006 103 49 18727 18732 17121991 10.1073/pnas.0606298103
215. Mitochondrial respiratory inhibition and oxidative stress elevate beta-secretase (BACE1) proteins and activity in vivo in the rat retina. K Xiong H Cai XG Luo RG Struble RW Clough XX Yan, Exp Brain Res 2007 17429617
216. beta-Secretase expression in normal and functionally deprived rat olfactory bulbs: inverse correlation with oxidative metabolic activity. XX Yan K Xiong XG Luo RG Struble RW Clough, J Comp Neurol 2007 501 1 52 69 10.1002/cne.21239 17206602
217. Statins and the risk of dementia. H Jick GL Zornberg SS Jick S Seshadri DA Drachman, Lancet 2000 356 1627 1631 10.1016/S0140-6736(00)03155-X 11089820
218. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. B Wolozin W Kellman P Ruosseau GG Celesia G Siegel, Arch Neurol 2000 57 10 1439 1443 10.1001/archneur.57.10.1439 11030795
219. Lipid dynamics in neurons. JE Vance B Karten H Hayashi, Biochem Soc Trans 2006 34 Pt 3 399 403 16709172
220. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. G Li R Higdon WA Kukull E Peskind K Van Valen Moore D Tsuang G van Belle W McCormick JD Bowen L Teri GD Schellenberg EB Larson, Neurology 2004 63 9 1624 1628 15534246
221. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. PP Zandi DL Sparks AS Khachaturian J Tschanz M Norton M Steinberg KA Welsh-Bohmer JC Breitner, Arch Gen Psychiatry 2005 62 2 217 224 10.1001/archpsyc.62.2.217 15699299
222. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. K Rockwood, Acta Neurol Scand Suppl 2006 185 71 77 10.1111/j.1600-0404.2006.00688.x 16866914
223. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. DL Sparks MN Sabbagh DJ Connor J Lopez LJ Launer P Browne D Wasser S Johnson-Traver J Lochhead C Ziolwolski, Arch Neurol 2005 62 5 753 757 10.1001/archneur.62.5.753 15883262
224. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. X Zhang K Zhou R Wang J Cui SA Lipton FF Liao H Xu YW Zhang, J Biol Chem 2007 282 15 10873 10880 10.1074/jbc.M608856200 17303576
225. Leaky scanning and reinitiation regulate BACE1 gene expression. W Zhou W Song, Mol Cell Biol 2006 26 9 3353 3364 16611980 10.1128/MCB.26.9.3353-3364.2006
226. Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. LE Huang WG Willmore J Gu MA Goldberg HF Bunn, J Biol Chem 1999 274 13 9038 9044 10.1074/jbc.274.13.9038 10085152
227. HIF1 and oxygen sensing in the brain. FR Sharp M Bernaudin, Nat Rev Neurosci 2004 5 6 437 448 10.1038/nrn1408 15152194
228. Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1). I Blasko R Beer M Bigl J Apelt G Franz D Rudzki G Ransmayr A Kampfl R Schliebs, J Neural Transm 2004 111 4 523 536 10.1007/s00702-003-0095-6 15057522
229. Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Y Wen O Onyewuchi S Yang R Liu JW Simpkins, Brain Res 2004 1009 1-2 1 8 10.1016/j.brainres.2003.09.086 15120577
230. The various aggregation states of beta-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. E Tamagno P Bardini M Guglielmotto O Danni M Tabaton, Free Radic Biol Med 2006 41 2 202 212 10.1016/j.freeradbiomed.2006.01.021 16814100
231. Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy. T Harkany I Abraham C Konya C Nyakas M Zarandi B Penke PG Luiten, Rev Neurosci 2000 11 4 329 382 11065280
232. Mechanism of toxicity in rotenone models of Parkinson's disease. TB Sherer R Betarbet CM Testa BB Seo JR Richardson JH Kim GW Miller T Yagi A Matsuno-Yagi JT Greenamyre, J Neurosci 2003 23 34 10756 10764 14645467
233. 3-nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme. LS Huang G Sun D Cobessi AC Wang JT Shen EY Tung VE Anderson EA Berry, J Biol Chem 2006 281 9 5965 5972 16371358 10.1074/jbc.M511270200
234. Vascular disorder in Alzheimer's disease: role in pathogenesis of dementia and therapeutic targets. BV Zlokovic, Adv Drug Deliv Rev 2002 54 12 1553 1559 10.1016/S0169-409X(02)00150-3 12453672
235. Stroke and the risk of Alzheimer disease. LS Honig MX Tang S Albert R Costa J Luchsinger J Manly Y Stern R Mayeux, Arch Neurol 2003 60 12 1707 1712 10.1001/archneur.60.12.1707 14676044
236. beta A4 amyloid protein deposition in brain after head trauma. GW Roberts SM Gentleman A Lynch DI Graham, Lancet 1991 338 8780 1422 1423 10.1016/0140-6736(91)92724-G 1683421
237. Distribution of beta-amyloid protein in the brain following severe head injury. DI Graham SM Gentleman A Lynch GW Roberts, Neuropathol Appl Neurobiol 1995 21 1 27 34 7770117
238. Caspase-mediated degeneration in Alzheimer's disease. DH Cribbs WW Poon RA Rissman M Blurton-Jones, Am J Pathol 2004 165 2 353 355 15277211
239. The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death. AC LeBlanc, Curr Alzheimer Res 2005 2 4 389 402 10.2174/156720505774330573 16248844
240. Expression of neuregulin and ErbB3 and ErbB4 after a traumatic lesion in the ventral funiculus of the spinal cord and in the intact primary olfactory system. T Lindholm S Cullheim M Deckner T Carlstedt M Risling, Exp Brain Res 2002 142 1 81 90 10.1007/s00221-001-0922-7 11797086
241. Role of the low-density lipoprotein receptor-related protein in beta-amyloid metabolism and Alzheimer disease. BT Hyman D Strickland GW Rebeck, Arch Neurol 2000 57 5 646 650 10.1001/archneur.57.5.646 10815129
242. Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family members. J Herms B Anliker S Heber S Ring M Fuhrmann H Kretzschmar S Sisodia U Muller, Embo J 2004 23 20 4106 4115 15385965 10.1038/sj.emboj.7600390
243. Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. P Wang G Yang DR Mosier P Chang T Zaidi YD Gong NM Zhao B Dominguez KF Lee WB Gan H Zheng, J Neurosci 2005 25 5 1219 1225 10.1523/JNEUROSCI.4660-04.2005 15689559
244. The functions of the amyloid precursor protein gene. PK Panegyres, Rev Neurosci 2001 12 1 1 39 11236063